A Phase 2 interventional study of Apremilast and Apremilast in Psoriasis, Psoriatic Arthritis and Psoriasis Arthropatica, sponsored by Amgen. Completed at 56 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-05-07.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.
Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 2 in phase 2, and was the 7th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
Tanta University · Sites in Egypt
Ages 18–70
Amgen
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 254 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 219 across the 17 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 7 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
21 studies in Arthritis, Psoriatic by Amgen: 1 open now, 1 under way, none of them phase 3. Of 20 finished, 13 (65%) have results posted.
Among the 21 studies in Arthritis, Psoriatic by Amgen, this one is the 7th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2013, is one of 2 in phase 2, and was the 10th registered.
Amgen’s Arthritis, Psoriatic studies by the year they started, since 2000.
2 of the studies testing apremilast in Arthritis, Psoriatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07398651Tanta UniversityApremilast and Adalimumab in Psoriatic Arthritis Patients | 2026-12-30 |
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing apremilast in Arthritis, Psoriatic, from their registry updates:
Among Amgen’s 21 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.
This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of apremilast 20 mg twice a day (BID), apremilast 30 mg BID, and placebo in Japanese participants with moderate to severe plaque psoriasis.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
This study's enrollment of 254 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Browse Arthritis, Psoriatic studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Prior medical history of suicide attempt or major psychiatric illness requiring hospitalization within the last 3 years
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apremilast 20 mg tablets orally twice a day (BID)
Drug: Apremilast · Drug: Placebo
Apremilast 30 mg tablets orally BID
Drug: Apremilast · Drug: Placebo
Identically-appearing placebo tablets BID for 16 weeks followed by participants being re-randomized in a blinded fasion to apremilast 20 mg or 30mg tablets BID for 52 weeks
Drug: Placebo
20 mg tablet BID for 68 weeks
Also known as: CC-10004, Otzela
20 mg tablet BID for 68 weeks
Also known as: CC-10004, Otzela
Placebo tablet BID for 16 weeks
Percentage of Participants Who Achieved a 75% Improvement (Response) From Baseline in the Psoriasis Area and Severity Index (PASI-75) at Week 16
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.
Time frame: Baseline to Week 16
Percentage of Participants Who Achieved a Static Physician's Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Point Reduction From Baseline to Week 16
The sPGA is a measure of psoriasis disease severity at the time of evaluation by the Investigator. It does not compare assessments across visits or rely on investigator recall or prior disease. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examines all of the lesions on the participant and assigns a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equals the overall sPGA score.
Time frame: Baseline to Week 16
Percent Change From Baseline in the Psoriasis Affected Body Surface Area (BSA) at Week 16
BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the subject's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area.
Time frame: Baseline to Week 16
Percent Change From Baseline in the Psoriasis Area and Severity Index (PASI) Score
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI is a validated instrument that has become standard in clinical trials for psoriasis. The PASI scores range from 0 to 72, with higher scores reflecting a greater disease severity.
Time frame: Baseline to Week 16
Percentage of Participants Who Achieved a 50% Improvement From Baseline (Response) Reduction in the PASI-50 at Week 16
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement is missing.
Time frame: Baseline to Week 16
Change From Baseline in Pruritus Visual Analogue Scale 100-mm (VAS) at Week 16
The pruritus visual analog scale (VAS) was used to measure the amount of itching and discomfort a participant experiences. Participant's assessment of pruritus (Itch) asked: On average, how much itch have you had because of your condition in the past week? Higher scores correspond to more severe symptom or disease. The participant places a vertical line on a 100-mm VAS on which the left-hand boundary represents no itch at all and the right-hand boundary represents the worst itch imaginable. The distance from the vertical line to the left-hand boundary is recorded. VAS scores range from 0 to 100 mm, where higher scores correspond to worse pruritis (itch).
Time frame: Baseline to Week 16
Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16
Dermatology Life Quality Index (DLQI) was developed as a practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains 10 items dealing with the participants skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score has a possible range from 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.
Time frame: Baseline to Week 16
Change From Baseline in Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 at Week 16
SF-36 is a 36-item general health status instrument often used in clinical trials and health services research. It consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better quality of life (better functioning)
Time frame: Baseline to Week 16
Number of Participants Who Achieved an American College of Rheumatology Criteria (ACR) 20% Improvement (ACR 20)
The ACR 20 is defined as a 20% improvement in joint tenderness (78 joint count) and joint swelling scores (76 joint count) compared to baseline plus 20% improvements in 3 of the following 5 assessments (compared to baseline): subject global assessment of disease activity (measured on a 100-mm visual analog scale \[VAS\]); physician global assessment of disease activity (measured on a 100-mm VAS); subject self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\] score); subject assessment of pain (measured on a 100-mm VAS); and CRP level.
Time frame: Baseline to Week 16
Percent Change From Baseline Psoriatic Arthritis Pain Visual Analogue Scale (VAS)
Change from baseline in psoriatic arthritis pain 100-mm VAS; The participant places a vertical line on a 100-mm VAS on which the left-hand boundary represents no pain at all and the right-hand boundary represents the worst possible pain. The distance from the vertical line to the left-hand boundary is recorded.
Time frame: Baseline to Week 16
Percent Change From Baseline in Physical Function Assessment Using the Health Assessment Questionnaire Disability Index (HAQ-DI)
Change from baseline in physical function assessment using HAQ-DI; The HAQ-DI is a 20-question, self-administered instrument that measures the subject's functional ability on a 4-level difficulty scale (0-3, with 0 representing normal or no difficulty; and 3 representing inability to perform). Eight categories of functioning are included: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities.
Time frame: Baseline to Week 16
Number of Participants With Adverse Events (AE) in the Placebo Controlled Phase
An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.
Time frame: Baseline to Week 16
Number of Participants With Adverse Events (AE) in the During the Apremilast-exposure Period
An AE was any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.
Time frame: From the first dose of apremilast (either Week 0 or Week 16 for participants originally randomized to placebo who were re-randomized at Week 16) until 28 days after the last dose of apremilast.
Participants must have had a diagnosis of chronic, stable plaque psoriasis at least 6 months prior to screening and which was considered inappropriate for topical therapy (e.g, based on the severity of the disease and extent of affected area) or could not be adequately controlled/treated with topical therapy to qualify for the study.
| Milestone | Placebo | Apremilast 20 mg | Apremilast 30 mg | Placebo-Apremilast 20 mg | Placebo-Apremilast 30 mg |
|---|---|---|---|---|---|
| Started | 84 | 85 | 85 | 0 | 0 |
| Completed | 72 | 69 | 76 | 0 | 0 |
| Not completed | 12 | 16 | 9 | 0 | 0 |
| Withdrew: Adverse event | 3 | 10 | 6 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 2 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 4 | 1 | 0 | 0 |
| Milestone | Placebo | Apremilast 20 mg | Apremilast 30 mg | Placebo-Apremilast 20 mg | Placebo-Apremilast 30 mg |
|---|---|---|---|---|---|
| Started | 0 | 69 | 76 | 36 | 35 |
| Completed | 0 | 56 | 65 | 33 | 30 |
| Not completed | 0 | 13 | 11 | 3 | 5 |
| Withdrew: Adverse event | 0 | 6 | 3 | 3 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 5 | 4 | 0 | 1 |
| Withdrew: Principal investigator signature missing | 0 | 1 | 2 | 0 | 2 |
| Milestone | Placebo | Apremilast 20 mg | Apremilast 30 mg | Placebo-Apremilast 20 mg | Placebo-Apremilast 30 mg |
|---|---|---|---|---|---|
| Started | 12 | 82 | 83 | 36 | 33 |
| Completed | 12 | 79 | 82 | 36 | 33 |
| Not completed | 0 | 3 | 1 | 0 | 0 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.
| percentage of participants | Placebo | Apremilast 20mg | Apremilast 30mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a 75% Improvement (Response) From Baseline in the Psoriasis Area and Severity Index (PASI-75) at Week 16 | 7.1 | 23.5 | 28.2 |
The sPGA is a measure of psoriasis disease severity at the time of evaluation by the Investigator. It does not compare assessments across visits or rely on investigator recall or prior disease. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examines all of the lesions on the participant and assigns a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equals the overall sPGA score.
| percentage of participants | Placebo | Apremilast 20mg | Apremilast 30mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a Static Physician's Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Point Reduction From Baseline to Week 16 | 8.8 | 23.9 | 29.6 |
BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the subject's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area.
| percent change | Placebo | Apremilast 20mg | Apremilast 30mg |
|---|---|---|---|
| Percent Change From Baseline in the Psoriasis Affected Body Surface Area (BSA) at Week 16 | 7.5 ± 5.56 | -21.6 ± 5.52 | -30.5 ± 5.51 |
The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI is a validated instrument that has become standard in clinical trials for psoriasis. The PASI scores range from 0 to 72, with higher scores reflecting a greater disease severity.
| percent change | Placebo | Apremilast 20mg | Apremilast 30mg |
|---|---|---|---|
| Percent Change From Baseline in the Psoriasis Area and Severity Index (PASI) Score | -3.7 ± 5.55 | -33.1 ± 5.51 | -43.1 ± 5.50 |
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement is missing.
| percentage of participants | Placebo | Apremilast 20mg | Apremilast 30mg |
|---|---|---|---|
| Percentage of Participants Who Achieved a 50% Improvement From Baseline (Response) Reduction in the PASI-50 at Week 16 | 21.4 | 41.2 | 50.6 |
The pruritus visual analog scale (VAS) was used to measure the amount of itching and discomfort a participant experiences. Participant's assessment of pruritus (Itch) asked: On average, how much itch have you had because of your condition in the past week? Higher scores correspond to more severe symptom or disease. The participant places a vertical line on a 100-mm VAS on which the left-hand boundary represents no itch at all and the right-hand boundary represents the worst itch imaginable. The distance from the vertical line to the left-hand boundary is recorded. VAS scores range from 0 to 100 mm, where higher scores correspond to worse pruritis (itch).
| units on a scale | Placebo | Apremilast 20mg | Apremilast 30mg |
|---|---|---|---|
| Change From Baseline in Pruritus Visual Analogue Scale 100-mm (VAS) at Week 16 | 7.1 ± 2.86 | -7.5 ± 2.84 | -17.7 ± 2.83 |
Dermatology Life Quality Index (DLQI) was developed as a practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains 10 items dealing with the participants skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score has a possible range from 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.
| units on a scale | Placebo | Apremilast 20mg | Apremilast 30mg |
|---|---|---|---|
| Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16 | 1.3 ± 0.53 | -0.5 ± 0.53 | -2.2 ± 0.52 |
SF-36 is a 36-item general health status instrument often used in clinical trials and health services research. It consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better quality of life (better functioning)
| units on a scale | Placebo | Apremilast 20mg | Apremilast 30mg |
|---|---|---|---|
| Change From Baseline in Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 at Week 16 | -1.59 ± 0.953 | -0.71 ± 0.953 | 0.27 ± 0.948 |
The ACR 20 is defined as a 20% improvement in joint tenderness (78 joint count) and joint swelling scores (76 joint count) compared to baseline plus 20% improvements in 3 of the following 5 assessments (compared to baseline): subject global assessment of disease activity (measured on a 100-mm visual analog scale \[VAS\]); physician global assessment of disease activity (measured on a 100-mm VAS); subject self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\] score); subject assessment of pain (measured on a 100-mm VAS); and CRP level.
No measurements were reported for this outcome.
Change from baseline in psoriatic arthritis pain 100-mm VAS; The participant places a vertical line on a 100-mm VAS on which the left-hand boundary represents no pain at all and the right-hand boundary represents the worst possible pain. The distance from the vertical line to the left-hand boundary is recorded.
No measurements were reported for this outcome.
Change from baseline in physical function assessment using HAQ-DI; The HAQ-DI is a 20-question, self-administered instrument that measures the subject's functional ability on a 4-level difficulty scale (0-3, with 0 representing normal or no difficulty; and 3 representing inability to perform). Eight categories of functioning are included: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities.
No measurements were reported for this outcome.
An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.
| participants | Placebo | Apremilast 20mg | Apremilast 30mg |
|---|---|---|---|
| ≥ At least 1 TEAE | 35 | 49 | 44 |
| ≥ 1 Drug-related TEAE | 8 | 18 | 25 |
| ≥ At least 1 Severe TEAE | 1 | 4 | 0 |
| ≥ 1 Serious TEAE | 0 | 4 | 0 |
| Any Serious Drug-related TEAE | 0 | 2 | 0 |
| ≥ 1 TEAE leading to Drug Interruption | 2 | 2 | 0 |
| ≥ 1 TEAE Leading to Drug Withdrawal | 4 | 10 | 6 |
| ≥ 1 TEAE Leading to Death | 0 | 0 | 0 |
An AE was any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.
| participants | Apremilast 20mg | Apremilast 30mg |
|---|---|---|
| ≥ At Least 1 TEAE | 94 | 89 |
| ≥ 1 Drug-related TEAR | 34 | 37 |
| ≥ At Least 1 Severe TEAE | 12 | 2 |
| ≥ 1 Serious TEAE | 11 | 2 |
| Any Serious Drug-related TEAE | 5 | 0 |
| ≥ 1 TEAE leading to Drug Interruption | 6 | 2 |
| ≥ 1 TEAE Leading to Drug Withdrawal | 19 | 10 |
| ≥ 1 TEAE Leading to Death | 1 | 0 |
Collected over AEs are reported for the 16-week placebo-controlled phase and up to 68 weeks for those who received apremilast during the study; TEAEs were recorded from the date of the first dose of IP received to no later than 28 days after the last dose of IP. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Weeks 0-16) | — | 0/84 (0%) | 9/84 (10.7%) |
| Apremilast 20mg BID (Weeks 0-16) | — | 4/85 (4.7%) | 16/85 (18.8%) |
| Apremilast 30mg BID (Weeks 0-16) | — | 0/85 (0%) | 18/85 (21.2%) |
| Apremilast 20mg BID (Weeks 0-68) | — | 11/121 (9.1%) | 35/121 (28.9%) |
| Apremilast 30mg BID (Weeks 0-68) | — | 2/120 (1.7%) | 40/120 (33.3%) |
| Event | Placebo (Weeks 0-16) | Apremilast 20mg BID (Weeks 0-16) | Apremilast 30mg BID (Weeks 0-16) | Apremilast 20mg BID (Weeks 0-68) | Apremilast 30mg BID (Weeks 0-68) |
|---|---|---|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/84 | 1/85 | 0/85 | 2/121 | 0/120 |
| Coronary artery stenosisCardiac disorders | 0/84 | 1/85 | 0/85 | 1/121 | 0/120 |
| Arthritis bacterialInfections and infestations | 0/84 | 1/85 | 0/85 | 1/121 | 0/120 |
| Cerebral haemorrhageNervous system disorders | 0/84 | 1/85 | 0/85 | 1/121 | 0/120 |
| PeriodontitisGastrointestinal disorders | 0/84 | 0/85 | 0/85 | 0/121 | 1/120 |
| Intraocular pressure increasedInvestigations | 0/84 | 0/85 | 0/85 | 0/121 | 1/120 |
| Cardiac failure congestiveCardiac disorders | 0/84 | 0/85 | 0/85 | 1/121 | 0/120 |
| Bile duct stoneHepatobiliary disorders | 0/84 | 0/85 | 0/85 | 1/121 | 0/120 |
| PneumoniaInfections and infestations | 0/84 | 0/85 | 0/85 | 1/121 | 0/120 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/84 | 0/85 | 0/85 | 1/121 | 0/120 |
| Event | Placebo (Weeks 0-16) | Apremilast 20mg BID (Weeks 0-16) | Apremilast 30mg BID (Weeks 0-16) | Apremilast 20mg BID (Weeks 0-68) | Apremilast 30mg BID (Weeks 0-68) |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/84 | 10/85 | 10/85 | 28/121 | 35/120 |
| DiarrhoeaGastrointestinal disorders | 1/84 | 7/85 | 8/85 | 10/121 | 12/120 |
| Abdominal discomfortGastrointestinal disorders | 1/84 | 1/85 | 6/85 | 3/121 | 8/120 |
Modified Intent-to-treat Population = (mITT) population consisted of all participants who were randomized and received at least one dose of investigational product (IP). Participants were included in the treatment group in which they were randomized.
| Age, Continuous(years) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| Mean | 48.3 ± 11.98 | 52.2 ± 12.54 | 51.7 ± 12.73 | 50.8 ± 12.49 |
| Sex: Female, Male(Participants) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| Female | 22 | 16 | 14 | 52 |
| Male | 62 | 69 | 71 | 202 |
| Region of Enrollment(Participants) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| Japan | 84 | 85 | 85 | 254 |
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Jul 2013 to primary completion in Nov 2014, 16 months.
Results were first posted in Mar 2020, 5 years 4 months after primary completion. A results delay was requested in Sep 2015.
Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast